E. Taguchi

Development and evaluation of a novel antibody-photon absorber conjugate reveals the possibility of photoimmunotherapy-induced vascular occlusion during treatment in vivo

K. Tomizuka, J. Enokizono, W. Piao, 2018, Oncotarget.

In vitro and in vivo activities of KRN330, a fully human monoclonal antibody against colon cancer.

M. Takahashi, N. Sawada, E. Taguchi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 2431: In vivo antibody binding to tumor in xenograft rodent models and colorectal cancer patients treated with anti-A33 antibody KRN330

Suzanne F. Jones, J. Berlin, E. Chan, 2010 .

Total Synthesis of Two 8‐Oxoprotoberberine Alkaloids: Alangiumkaloids A and B

M. Ishikura, T. Choshi, N. Hatae, 2018 .

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

Yasunari Fujiwara, Nicolas Guilbaud, M. Shibuya, 2006, Cancer research.

Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window

Kazuhide Nakamura, A. Yamamoto, E. Taguchi, 2006, Molecular Cancer Therapeutics.

KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.

M. Shibuya, K. Kubo, T. Isoe, 2004, Molecular cancer therapeutics.

Anti‐tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model

M. Shibuya, T. Isoe, Kazuhide Nakamura, 2008, Cancer science.

In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.

T. Ishii, K. Kubota, Maki Hasegawa, 2019, Journal of controlled release : official journal of the Controlled Release Society.

One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.

Kazuhiro Masuda, Tsuyoshi Yamaguchi, Eri Taguchi, 2016, Bioconjugate chemistry.

Leukocyte behavior in angiogenic vessels is affected by tumor-derived nitric oxide.

N. Ohshima, C. Miyoshi, E. Taguchi, 2003, The Japanese journal of physiology.